Clinical Trials Browser

Pdgfra-Associated Chronic Eosinophilic Leukemia, Congenital Abnormalities, Carcinoma, Ovarian Epithelial, Blast Crisis, Breast Neoplasms, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myeloproliferative Disorders, Nausea, Neoplasms, Neuroblastoma, Sezary Syndrome, Testicular Neoplasms, Vomiting, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00600353 2017-03-09

Multi-day Doses in Prevention of Nausea and Emesis

Phase 2 Completed

20 enrolled 8 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Nausea, Neoplasms

NCT00250718 2015-08-03

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

Phase 2 Terminated

17 enrolled 4 charts

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms

Clinical Trials

VIWA-1

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant

Multi-day Doses in Prevention of Nausea and Emesis

Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach